Suzanne Conzen to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Suzanne Conzen has written about Drug Resistance, Neoplasm.
Connection Strength
0.550
-
Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression. Clin Cancer Res. 2000 Oct; 6(10):4043-8.
Score: 0.138
-
Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol Oncol. 2015 Sep; 138(3):656-62.
Score: 0.096
-
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 2014 Apr; 5(2):72-89.
Score: 0.088
-
Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6163-72.
Score: 0.085
-
Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression. Breast Cancer Res Treat. 2012 Sep; 135(2):469-79.
Score: 0.078
-
Overcoming oncogene addiction in breast and prostate cancers: a comparative mechanistic overview. Endocr Relat Cancer. 2021 02; 28(2):R31-R46.
Score: 0.035
-
Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer. Clin Cancer Res. 2018 07 15; 24(14):3433-3446.
Score: 0.029